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Objective. The objective of this trial was to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female
vaginal transmission of HIV infection among women at high risk. Methodology/Principal Findings. This was a Phase 3,
double-blind, randomized, placebo-controlled trial. Participants made up to 12 monthly visits for HIV testing, adverse event
reporting, and study product supply. The study was conducted between March 2004 and February 2006 in Accra and Kumasi,
Ghana. We enrolled 2142 HIV-negative women at high risk of HIV infection, and randomized them to SAVVY or placebo gel.
Main outcome measures were the incidence of HIV-1 and HIV-2 infection as determined by detection of HIV antibodies from
oral mucosal transudate specimens and adverse events. We accrued 790 person-years of follow-up in the SAVVY group and 772
person-years in the placebo group. No clinically significant differences in the overall frequency of adverse events, abnormal
pelvic examination findings, or abnormal laboratory results were seen between treatment groups. However, more participants
in the SAVVY group reported reproductive tract adverse events than in the placebo group (13.0% versus 9.4%). Seventeen HIV
seroconversions occurred; eight in participants randomized to SAVVY and nine in participants receiving placebo. The Kaplan-
Meier estimates of the cumulative probability of HIV infection through 12 months were 0.010 in the SAVVY group and 0.011 in
the placebo group (p=0.731), with a hazard ratio (SAVVY versus placebo) of 0.88 (95% confidence interval 0.33, 2.27). Because
of a lower-than-expected HIV incidence, we were unable to achieve the required number of HIV infections (66) to obtain the
desired study power. Conclusions/Significance. SAVVY was not associated with increased adverse events overall, but was
associated with higher reporting of reproductive adverse events. Our data are insufficient to conclude whether SAVVY is
effective at preventing HIV infection relative to placebo. Trial Registration. ClinicalTrials.gov NCT00129532
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INTRODUCTION
Topical microbicides are designed to inhibit the sexual transmis-
sion of Human Immunodeficiency Virus (HIV) and other disease
pathogens. They offer a female-controlled prophylactic option in
situations where male condom use cannot be negotiated. Marketed
chemical spermicides, which show some activity against sexually
transmitted pathogens in vitro, have been evaluated as topical
microbicides. However, no clinical studies have yet demonstrated
that these products can prevent HIV infection, and spermicides
with the surfactant nonoxynol-9 (N-9) have caused mucosal
erosion and ulceration, which may increase the risk of HIV
transmission [2–4].
Several in vitro studies [5] have suggested that C31G (SAVVYH,
Cellegy Pharmaceuticals [formerly BIOSYN, Inc.], Huntington
Valley, Pennsylvania) has a potent effect on enveloped HIV by
disrupting the outer membrane. However, because its mechanism of
action is similar to N-9 [6;7], some have raised concerns about the
safety of SAVVY. In pre-clinical studies, SAVVY demonstrated
minimal toxicity at 0.001% concentration, as measured by the cell
proliferation assay, and no toxicity to mammalian cells at 0.0003%,
as measured by the MTT assay [5]. In addition, 5 Phase 1 clinical
studies, including a total of 121 women and 24 men exposed to
SAVVY, have been conducted using three concentrations of
SAVVY (0.5%, 1.0%, 1.7%). No serious or severe adverse events
relatedtouseof1.0%SAVVYgelwerereportedduringthesestudies
[8–10].We investigated the safetyand effectiveness of 1.0% SAVVY
inpreventing HIV infection ina population of young,sexually active
women at high risk for acquiring HIV infection.
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
We conducted this randomized, double-blind, placebo-controlled
trial between January 2004 and March 2006 in Accra and
Kumasi, Ghana. We enrolled HIV-antibody negative, non-
pregnant women 18 to 35 years old who were at risk of HIV
Academic Editor: Keymanthri Moodley, University of Stellenbosch, South Africa
Received September 5, 2007; Accepted September 6, 2007; Published December
19, 2007
Copyright:  2007 Peterson et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: This study was supported by funds from the United States Agency for
International Development (USAID) under Cooperative Agreement CCP-A-00-95-
00022-02 and GPO-A-00-05-00022-00. Cellegy Pharmaceuticals (formerly BIOSYN,
Inc.) (Huntington Valley, Pennsylvania) donated the investigational product
(SAVVY and placebo-gel applicators) evaluated in this study.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: KNanda@fhi.org
PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1312infection because of having a mean of three or more coital acts per
week and two or more sexual partners in the 3 months before
screening. Study participants were recruited from areas within
each city that were considered high HIV transmission areas,
including markets, bars, and hotels. Although we did not
specifically ask as part of the clinical trial procedures if the
participants were sex workers, most exchanged sex for money.
Special ethical considerations were taken into account because of
the potential vulnerability of this population. We included women
who agreed to: use study gel as directed and follow study
procedures; report self-medication with antibiotics during study
participation; and avoid use spermicides or other vaginal
contraceptives or lubricants during the study. We excluded
women who: were intending pregnancy; had a history of latex
allergy; were injection drug users; or had gynecological conditions
that could affect the safety or effectiveness of the study gel.
Ethics
We developed strategies to protect the confidentiality and
autonomy of the participants, increase/ensure comprehension of
the informed consent and research methods, and promote access
to resources and services during and after the trial. The study
protocol and informed consent forms were approved by 1) the
Committee on Human Research, Publications and Ethics, School
of Medical Sciences, University of Science & Technology, Kumasi,
Ghana, 2) Noguchi Memorial Institute for Medical Research IRB,
University of Ghana, Legon, Ghana, and 3) the Protection of
Human Subjects Committee, Family Health International, USA.
All participants provided written informed consent in their
preferred language. Illiterate participants were read the informed
consent forms verbatim in the presence of a witness, and provided
a mark or thumbprint in lieu of signature.
Interventions
During recruitment, study staff explained the general purpose of
the study and the eligibility requirements. If eligible, women were
referred to one of two study clinics in Kumasi or Accra. At the
screening visit, women were interviewed to confirm understanding
and willingness to comply with study requirements, completed
written informed consent, received HIV pretest and condom
counseling, and underwent oral mucosal transudate (OMT) rapid
HIV testing. All participants received HIV post-test counseling,
physical and pelvic examinations (including vaginal wet mount to
support the diagnosis for bacterial vaginosis, trichomoniasis, or
vaginal candidiasis), urine pregnancy tests, and STI (syphilis,
gonorrhea, and chlamydia) tests. Women with reactive OMT
rapid HIV tests received ELISA to confirm HIV status. We asked
potential participants to return 4 weeks after their screening visit
to receive the results of their STI and confirmatory HIV tests, if
applicable.
At this second visit, participants received a detailed explanation
of study procedures, signed or marked a consent form for
enrollment, received HIV counseling, provided urine for preg-
nancy testing, provided another OMT sample for HIV testing,
and if eligible were randomized to receive either SAVVY or
placebo. Study staff gave each eligible participant her first month’s
supply of study product after she had been randomized. Clinic
staff counseled participants to use the gel vaginally before each act
of sexual intercourse (and to insert a second dose if more than one
hour had elapsed between the first application and sexual
intercourse), emphasized that the gel had unknown effectiveness
for preventing HIV, distributed condoms, and counseled partic-
ipants to use condoms for all sexual contacts with all partners. The
informed consent form stated that: ‘‘We do not know the effects
and safety of the gel during pregnancy. Pregnant women may not
join this study. If you become pregnant during the study you
should tell your study doctor or nurse right away. Your study gel
will be stopped and the study doctor will discuss your choices with
you.’’
At each monthly follow-up visit, participants underwent OMT
HIV and pregnancy testing, AE assessment, STI risk reduction
counseling, and study product and condom re-supply. Participants
responded to structured questionnaires on their interval sexual
behavior (including coital activity, and gel and condom use),
experience using the gel, and were reminded of study concepts
discussed during the informed consent process. If clinically
indicated, participants underwent physical examination and STI
testing. Study staff documented whether product use was
interrupted temporarily or permanently for any of the following
reasons: participant ran out of supplies, investigator withdrew
study product in the interest of the safety and well being of the
participant, positive pregnancy test result, or confirmed HIV
infection. Pregnant women were allowed to resume study product
use after pregnancies had ended. Study staff referred participants
infected with HIV during the study to local HIV-related
psychological, social, and medical services (such as viral load,
CD4 level, and HIV resistance testing) as well as antiretroviral
drug therapy when needed. If a participant missed a scheduled
follow-up appointment, study staff made up to 3 attempts to
contact that participant and reschedule the appointment (ideally to
occur within 2 weeks of the original appointment). If the
participant could not be located after 3 attempts, no further
efforts were made to find her, but her file remained open until
study closeout. If the participant did not return to the study before
the study was closed, she was considered lost to follow-up. The
‘‘lost to follow-up’’ designation was not made for any participant
until the closing date of the study.
Objective
The objective of this trial was to determine the effectiveness of
1.0% C31G in preventing male-to-female vaginal transmission of
HIV infection among women at high risk.
Outcomes
The primary measure of effectiveness was infection with HIV-1 or
HIV-2, measured by detecting antibodies in oral mucosal
transudate (OMT) (OraQuickH ADVANCE Rapid HIV-1/2
Antibody Test, Orasure Technologies) and confirmed by an
enzyme-linked immunosorbent assay (ELISA) (Genetic Systems
TM
HIV-1/HIV-2 Plus O ELISA from BioRad) and/or Western Blot
(Genetic Systems
TM HIV-1 Western Blot, BioRad) from a finger
prick or serum specimen. We evaluated safety by comparing the
incidence of adverse events (AEs) including pelvic exam findings
and sexually transmitted infections (STIs).
Sample Size
We estimated that a sample size of 2142 participants (1,071 in
each treatment group) would give us 80% power to detect a 50%
difference in the HIV infection rate (two-sided log-rank test,
a=0.05 significance level) between the two groups. We assumed
the rate of HIV infection in the control group to be 5/100 person-
years and loss to follow-up to be 20%; approximately 66 total HIV
infections were needed to achieve the desired power. Our protocol
included plans for assessing (in a blinded manner) whether
additional participants would be needed to observe the required
66 events.
SAVVY Gel for HIV Prevention
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We randomized enrolled participants into either the SAVVY or
placebo arm using a 1:1 allocation ratio. A statistician not
otherwise involved with the study developed the allocation
sequence using a computer random number generator and
randomly varied permuted-blocks of 12, 18, and 24. Six label
colors (three SAVVY and three placebo) were used to differentiate
the otherwise identically packaged gels. Randomization was
stratified by study site. We used sequentially numbered, sealed
opaque envelopes to assign participants to one of six color groups
after they had qualified for the study and signed the consent form.
The randomization envelopes were maintained in a secure office
and were not available to study staff until the moment of
randomization. Each randomization envelope was used only once.
Participants, field study staff, monitors, statisticians, and other FHI
staff involved in the trial were not aware of which gel colors were
associated with SAVVY or placebo. Both SAVVY and placebo
gels were clear, with similar viscosity and pH, dispensed in 3.5 mL
doses with identical applicators.
The placebo gel was formulated to minimize any possible
effects—negative or positive—on study endpoints. It was isotonic
to avoid epithelial cell swelling or dehydration, and formulated at a
pH of 4.4 but with minimal buffering capacity. When mixed with
an equal volume of semen, the placebo gel induced only a trivial
decrease in semen pH (from 7.8 to 7.7). The placebo gel contained
hydroxyethylcellulose as a gelling agent, and its viscosity was
comparable to that of SAVVY. Hydroxyethylcellulose does not
have anti-HIV properties. The gel also contained sorbic acid as a
preservative; sorbic acid has no anti-HIV activity and is readily
metabolized by human cells.
Statistical Methods
For the primary effectiveness analysis we compared the probability
ofHIVinfectionfortheSAVVYandplacebogelgroupsusingatwo-
sided site-stratified, exact log-rank test (StatXact). We calculated
Kaplan-Meier estimates of HIV infection probabilities by treatment
group, pooled across sites. We used a proportional hazards
regression model to estimate the hazard ratio, along with a 95%
confidence interval, comparing the SAVVY group to the placebo
group for HIV incidence, controlling for site. Each HIV infection
onset datewasestimated as themidpoint betweenthe date ofthe first
positive test result and the previous, negative test date. A right
censoring time of 380 days was applied. Because the trial was
terminated well before reaching the number of HIV infections
targeted for pre-planned tests of effectiveness (i.e., before any of the
type I error was to be spent), p-values for analyses of effectiveness
should be interpreted as descriptive statistics. We calculated exact
95% confidence intervals for the relative risk of pre-specified priority
AEs within system organ classes under a Poisson assumption for the
event rates in each treatment group (StatXact). We compared
proportions of women with any pelvic exam findings or STDs
between treatment groups with a two-sided Mantel-Haenszel Chi-
Square Test stratified by site at the 0.05 significance level.
All primary and most secondary analyses were either conducted
on the Effectiveness Population which is the subset of the Intent-
to-Treat (ITT) Population for whom at least one post-enrollment
HIV evaluation is available, or the Safety Population which is the
subset of the ITT Population who ever returned after enrollment.
The Evaluable Population includes the same participants as the
Effectiveness Population but excludes all data collected from a
participant after her first documented interruption of product use.
Our data monitoring plan specified that the independent Data
Monitoring Committee (DMC), with access to treatment assign-
ments, would review AEs and primary safety and HIV
seroconversion data twice, after approximately 16 and 33 events,
respectively. However, testing for early evidence of effectiveness
was scheduled only to occur at the second of these two planned
looks and later when the target total number of events (66) was
obtained (i.e., the first look at the HIV seroconversion data was to
review the data for signs of harm) .
Monitors (trained in Good Clinical Practice) visited sites regularly
to review study eligibility, informed consent, protocol compliance,
laboratory procedures, source documents, product accountability,
and AEs. We attempted to get original hospital records, when
available, for serious adverse events (SAEs) and deaths.
RESULTS
Recruitment, Participant Flow, Numbers Analyzed
and Baseline Characteristics
Participants were recruited and enrolled into this study for
15 months, starting February 2004. A total of 3,490 women were
screened, from which we enrolled 2,142 participants into the study
(Figure 1). The primary reasons potential participants were not
enrolled were because they failed to return for enrollment, were
HIV-infected at baseline, or were pregnant. Overall loss to follow-
up after enrollment was approximately 15% (n=310). The loss-to-
follow-up rate was highest during the first month of study
participation, during which 40% of the overall loss to follow-up
(123 of 310 participants) occurred. Among these were 103
participants who never returned after their enrollment visit and
were therefore excluded from the primary safety analyses.
The first scheduled DMC safety review was repeated because
errors were found in the initial HIV seroconversion data due to
false positive ELISA testing. At the third DMC safety review
meeting, when there were 16 seroconversions in the database, we
informed the DMC that the study statistician estimated that
approximately 3,500 additional participants (beyond the 2,142
planned sample size) would be needed to achieve the required
number of HIV infections (66) to obtain the desired study power.
In light of this formidable challenge, we requested that the DMC
review the available outcome data by group (along with results of
conditional power calculations under a range of assumptions about
the true effect size) and provide a recommendation as to whether
the trial should continue or be terminated early. The DMC
recommended that the trial be stopped; we thus decided to
prematurely terminate the study in November 2005.
Due to premature termination of the study, 660 participants
exited the study before completing their Month 12 visit (Figure 1).
Twelve additional participants (0.6%) discontinued early (6 in each
treatment group), including one participant in each of the
treatment groups who died during follow-up. Other than the
deaths, which were unrelated to product use, no participants
withdrew early due to a medical reason. Most enrolled participants
in both groups were young (mean age 22.7), unmarried, and had
fewer than 9 years of education. Other demographic character-
istics and medical history were also similar (Table 1).
Sexual Behavior
At enrollment participants reported a mean coital frequency of 9–
10 acts per week (SAVVY 9.5; placebo 8.9) and a mean of 5.8
different partners in the last 30 days (in both groups). Approxi-
mately 2% of the participants (SAVVY 1.8%; placebo 2.5%)
reported having anal sex in the previous 30 days. During follow-
up, participants consistently reported a mean of 7 coital acts per
week, with a mean of 5–6 sexual partners in the previous 30 days.
Self-reported condom use increased from 40% during the last
SAVVY Gel for HIV Prevention
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remaining relatively constant throughout follow-up.
Although pregnant participants are included in the intent-to-
treat analysis, we asked these participants to stop gel use upon a
positive pregnancy test (they could return to product use after a
negative pregnancy test). A total of 383 participants in the SAVVY
group and 386 participants in the placebo group became pregnant
at least once during the study. The Kaplan-Meier pregnancy
probability at 12 months was 42.5 per 100 person-years in the
SAVVY group and 43.7 per 100 person-years in the placebo
group. Of the women who became pregnant during the study,
most (79%) were pregnant only once. However, approximately
19% were pregnant twice, and almost 2% were pregnant three
times during the course of the study. The median amount of time
without gel use due to pregnancy (among the participants who
became pregnant) was approximately 2 months, resulting in 151
person-years (or 10% of the total person-time) off product due to
pregnancy. Of the 942 total pregnancies detected during the study
(among 769 participants), pregnancy outcome information was
available for 606 pregnancies. Other than 13 spontaneous
abortions (4 in participants receiving SAVVY and 9 in participants
receiving placebo), no abnormal outcomes were reported. A total
of 40 live births (all normal) were reported to have occurred
among study participants.
Product Use
Participantsreportedthat they used thegelforanaverageof75% and
77% of coital acts in the SAVVY and placebo groups, respectively,
and reported condoms use for 89% and 90% of coital acts in the
SAVVY and placebo groups, respectively. They reported using both
gel and condoms for 70.1% and 71.7% of acts in the SAVVY and
placebo groups, respectively. Participants reported using neither gel
n o rc o n d o m sf o r6 . 2 %a n d5 . 3 %o fa c t si nt h eS A V V Ya n dp l a c e b o
groups, respectively. Gel use decreased with time in both groups
(from 86–87% during Month 1 to 67–71% during Month 12),
whereas condom use was more consistent. From these data, we
calculated that SAVVY or placebo gel was used alone (i.e., without a
condom) for approximately 5% of all vaginal acts and that condoms
were used alone (i.e.,without gel) for approximately16% of all vaginal
acts. We also calculated that SAVVY or placebo gel was used for
81% of vaginal acts during which a condom was also used, but for
only 43–47% of acts where no condom was used (Table 2).
Figure 1. Participant Trial Flow Diagram (P-Y, person years).
doi:10.1371/journal.pone.0001312.g001
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Approximately one-third of participants in both groups had adverse
events (33% in the SAVVY group and 29% in the placebo group),
with no significant differences in the overall frequency of AEs
between treatment groups. The most frequently reported AEs
included: malaria, abdominal pain, headache, genital pruritus,
vaginal candidiasis, general pain, bacterial vaginitis, and vaginal
discharge. No significant differences in frequency of AEs occurred
between treatment groups. However, more participants in the
SAVVY group had reproductive tract AEs, with an incidence of
14.5 per 100 person-years in the SAVVY group versus 10.9 per 100
person-years in the in the placebo group (rate ratio=1.33, 95%
confidence interval 0.99, 1.80, [Table 3]). The most frequently occur-
ring AEs with the reproductive tract were genital pruritus, vaginal
candidiasis, vaginal discharge, bacterial vaginitis, and vulvovaginitis.
In post hoc analyses that examined subgroups defined by self-
reported frequency of gel use, we found a greater treatment group
difference in the incidence of reported reproductive system and
breastdisorders(17.3per100person-yearsintheSAVVYgroupand
10.1per100person-yearsintheplacebogroup)amongthesubgroup
ofparticipants whose self-reported gel usewas at or belowthe overall
medianthanamongthesubgroupofparticipantswhoseself-reported
gel use was above the overall medium. Among participants whose
self-reported gel use was at or below the overallmedian the rate ratio
was 1.71 (95% confidence interval=1.13–2.61). Similarly, the rate
ratio was 1.64 (95% confidence interval=1.09–2.50) for the
subgroup of participants with self-reported sexual frequency at or
below the overall median (17.4 per 100 person-years in the SAVVY
group and 10.6 per 100 person-years in the placebo group).
Participants underwent pelvic examination and STI testing
during follow-up only if clinically indicated. During follow-up, 121
participants had pelvic examinations (63 in the SAVVY group and
58 in the placebo group). No significant differences were seen
between treatment groups for bacterial vaginosis, trichomoniasis,
or vaginal candidiasis on saline wet mounts.
Twenty-two SAEs were reported; 15 by participants in the
SAVVY group and 7 by participants in the placebo group. Only
one, gonorrhea, was classified by the investigator as possibly
related to the study product (the participant had received placebo).
Two deaths occurred during the course of the study. One was
suspected to be due to possible sickle cell crisis (the participant had
been randomized to SAVVY), and one was due to viral hepatitis
complicated by hepatic encephalopathy (the participant had been
randomized to placebo). No participant was asked to discontinue
study drug due to an AE.
Table 1. Baseline Characteristics (ITT Population)
......................................................................
SAVVY (N=1073) Placebo (N=1069)
Characteristic
Age 22.7 (3.6) 22.7 (3.6)
Marital status
Unmarried, not cohabiting 946 (88.2) 945 (88.4)
Education
# 9 years 831 (77.4) 812 (76.0)
Pregnancy history
Ever pregnant 782 (72.9) 782 (73.2)
Number of pregnancies 2.1 (1.4) 2.1 (1.4)
Number of vaginal deliveries 0.9 (1.0) 0.9 (0.9)
Contraceptive use
Condom 496(46.2) 516 (48.3)
None 423 (39.4) 397 (37.1)
Oral 122 (11.4) 125 (11.7)
Injectable 23 (2.1) 22 (2.1)
IUD 5 (0.5) 5 (0.5)
Other 4 (0.4) 4 (0.4)
History of STI 182 (17.0) 199 (18.6)
Previous spermicide use 91 (8.5) 77 (7.2)
Douching 578 (53.9) 555 (51.9)
Data reported as N(%) or mean (SD); SD=standard deviation, STI=sexually
transmitted infection
doi:10.1371/journal.pone.0001312.t001
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Table 2. Overall Estimates of Gel and Condom Use at Follow-
Up by Treatment Groups*
......................................................................
Overall
SAVVY N=1021 Placebo N=1008
Mean percentage of vaginal sex acts in the last 7 days with study gel
Mean (SD) 75.0 (24.0) 77.0 (23.1)
Range (median) 0–100 (81.6) 0–100 (83.0)
Mean percentage of vaginal sex acts in the last 7 days with a condom
Mean (SD) 88.6 (16.5) 89.5 (15.9)
Range (Median) 0–100 (94.9) 0–100 (96.0)
Mean percentage of vaginal sex acts in the last 7 days with both the study
gel and a condom
Mean (SD) 70.1 (26.5) 71.7 (25.8)
Range (Median) 0–100 (76.5) 0–100 (77.8)
Mean percentage of vaginal sex acts in the last 7 days with neither a
condom nor study gel
Mean (SD) 6.2 (11.8) 5.3 (10.7)
Range (Median) 0–100 ( 0.0) 0–100 ( 0.0)
Mean percentage of vaginal sex acts in the last 7 days with study gel only
(without a condom)
Mean (SD) 5.1 (17.6) 5.2 (17.9)
Range (median) 0–100 ( 0.0) 0–100 ( 0.0)
Mean percentage of vaginal sex acts in the last 7 days with a condom only
(without study gel)
Mean (SD) 16.4 (32.4) 16.5 (32.7)
Range (Median) 0–100 ( 0.0) 0–100 ( 0.0)
Mean percentage of vaginal sex acts in the last 7 days with study gel and a
condom
Mean (SD) 80.8 (35.8) 80.8 (36.2)
Range (Median) 0–100 ( 100) 0–100 ( 100)
Mean percentage of vaginal sex acts in the last 7 days with study gel when a
condom is not used
Mean (SD) 43.1 (47.3) 46.9 (47.9)
Range (Median) 0–100 ( 0.0) 0–100 (29.3)
*For each participant and variable of interest (e.g., percentage of vaginal acts
where study gel was used in the last 7 days prior to the follow-up visit), we first
calculated the participant’s mean value of the variable of interest across all of
their follow-up visits. (Follow-up visits where women reported 0 or a missing
number of vaginal sex acts in the last 7 days are excluded from the calculation
of a participant’s mean value.) The mean, SD, range, and median values of the
distributions of these mean values were then obtained for each treatment
group.
doi:10.1371/journal.pone.0001312.t002
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The overall HIV incidence rate was 1.09 per 100 person years (95%
confidence interval 0.63, 1.74). In the Effectiveness Population, we
observed 17 HIV seroconversions, 8 in the SAVVY group and 9 in
the placebo group. The Kaplan-Meier estimates of the cumulative
probabilityofHIVinfectionat12 monthswere0.010intheSAVVY
group and 0.011 in the placebo group (log-rank p=0.731), with a
hazard ratio (SAVVY versus placebo) of 0.88 (95% confidence
interval0.33,2.27).Ofthese17seroconversions,9wereinAccraand
8 occurred in Kumasi. Fifteen seroconversions (7 SAVVY; 8
placebo) occurred in participants younger than 25 years. Ten (5
SAVVY; 5 placebo) of the seroconverters had baseline coital
frequency at or below the median and 7 (3 SAVVY; 4 placebo) had
baseline coital frequency above the median.
When we repeated the analysis in the Evaluable Population, we
observed 11 HIV infections (4 in the SAVVY group; 7 in the
placebo group). The Kaplan-Meier estimates of the cumulative
probability of HIV infection at 12 months were 0.007 in the
SAVVY group and 0.012 in the placebo group, with a hazard
ratio of 0.57 (95% confidence interval of 0.17 to 1.94).
DISCUSSION
Interpretation and Overall Evidence
We stopped this study prematurely following recommendations of
an independent DMC because the HIV incidence among enrolled
participants was substantially lower than expected; we therefore
could not evaluate the effectiveness of SAVVY in preventing HIV
as intended. Due to the small number of events available for
analysis, this trial was unable to meet the objective of accessing the
effectiveness of SAVVY in preventing male-to-female transmission
of HIV. To date, no randomized clinical studies have identified a
microbicide that is effective at preventing HIV infection [11].
Lower-than-expected HIV incidence has been an increasing
problem in HIV prevention trials and the lower-than-expected
HIV incidence seen in this trial may have been due in part at least
3 factors: 1) a greater-than-expected effect of trial risk reduction
measures such as condom use, 2) participants who join clinical
trials may be more inclined to safer behavior than those in their
community who do not participate, and 3) an inaccurate estimate
of trial incidence due to changes in the local epidemic. The
Table 3. Selected Priority Adverse Events
..................................................................................................................................................
System Organ Class/ Preferred Term SAVVY (N=1027 ) Placebo (N=1012 )
Rate Ratio (95% CI),
SAVVY vs. Placebo
No. of
Events
No. of
Women
%o f
Women
IR* (per 100
person years)
No. of
Events
No. of
Women
%o f
Women
IR* (per 100
person years)
Reproductive system and breast disorders 140 107 10.4 14.5 120 80 7.9 10.9 1.33 (0.99, 1.80)
Amenorrhoea 3 3 0.3 0.4 0 0 0.0 0.0 INF
Cervicitis 0 0 0.0 0.0 1 1 0.1 0.1 0.00
Dysmenorrhoea 6 6 0.6 0.8 4 4 0.4 0.5 1.47
Dyspareunia 1 1 0.1 0.1 1 1 0.1 0.1 0.98
Genital abscess 1 1 0.1 0.1 2 2 0.2 0.3 0.49
Genital pruritus female 28 27 2.6 3.5 23 20 2.0 2.6 1.32
Genitourinary tract gonococcal infection 0 0 0.0 0.0 1 1 0.1 0.1 0.00
Menorrhagia 1 1 0.1 0.1 2 2 0.2 0.3 0.49
Menstruation irregular 7 7 0.7 0.9 7 6 0.6 0.8 1.14
Ovulation pain 1 1 0.1 0.1 1 1 0.1 0.1 0.98
Pelvic inflammatory disease 5 5 0.5 0.6 4 4 0.4 0.5 1.23
Post coital bleeding 1 1 0.1 0.1 1 1 0.1 0.1 0.98
Vaginal abscess 3 3 0.3 0.4 1 1 0.1 0.1 2.94
Vaginal burning sensation 0 0 0.0 0.0 3 2 0.2 0.3 0.00
Vaginal candidiasis 29 28 2.7 3.6 30 28 2.8 3.7 0.98
Vaginal discharge 16 16 1.6 2.0 13 11 1.1 1.4 1.43
Vaginal erythema 4 3 0.3 0.4 0 0 0.0 0.0 INF
Vaginal haemorrhage 0 0 0.0 0.0 1 1 0.1 0.1 0.00
Vaginal laceration 0 0 0.0 0.0 2 2 0.2 0.3 0.00
Vaginal pain 2 2 0.2 0.3 1 1 0.1 0.1 1.96
Vaginitis bacterial 19 19 1.9 2.4 16 14 1.4 1.8 1.33
Vulvovaginal ulceration 1 1 0.1 0.1 1 1 0.1 0.1 0.98
Vulvovaginitis 11 11 1.1 1.4 5 5 0.5 0.6 2.16
Vulvovaginitis trichomonal 1 1 0.1 0.1 0 0 0.0 0.0 INF
Gastrointestinal disorders 85 73 7.1 9.7 94 76 7.5 10.4 0.93 (0.67, 1.30)
Pregnancy, puerperium and perinatal
conditions
7 7 0.7 0.9 13 12 1.2 1.6 0.57 (0.19, 1.57)
Renal and urinary disorders 15 12 1.2 1.5 18 17 1.7 2.2 0.69 (0.30, 1.53)
*Incidence Rate
doi:10.1371/journal.pone.0001312.t003
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SAVVY Gel for HIV Prevention
PLoS ONE | www.plosone.org 6 December 2007 | Issue 12 | e1312incidence rate for this trial was estimated from our experience in
earlier trials in a similar population and was not specifically
measured in each population before starting the study.
Ensuring high product adherence is another important
challenge in the successful conduct of HIV prevention studies.
Low product use due to such factors as pregnancy, missed visits, or
participant’s choice compromises study power. Although partic-
ipants reported using the gel during approximately 76% of coital
acts, our calculations show that participants were more likely to
use gel if a condom was also used than when a condom was not
used (.80% gel use with condoms versus ,50% gel use without
condoms). Since the percent of gel use among risky acts (i.e., with
an HIV-infected partner) without condom use is a major
determinant of the overall level of effectiveness that can be
observed for a truly efficacious product, unless gel use can be
increased, studies designed to detect a 50% effect may not be able
to identify truly efficacious products[12]. We observed a
pregnancy probability at 12 months of 42.5 per 100 person-years
in the SAVVY group and 43.7 per 100 person-years in the placebo
group. If further studies demonstrate that SAVVY is an effective
contraceptive method in other populations, the lack of a difference
between the observed pregnancy rates for the SAVVY and
placebo groups in our study may indicate that the level of gel
adherence was even lower than the participants reported.
The likelihood of pregnancy in reproductive-age women having
multiple sexual encounters is quite high even with relatively high
condom use. Using Wilcox’s estimates of the probability of
pregnancy resulting after one or more unprotected act for each
day of the menstrual cycle (assuming 30 days per cycle and 12 cycles
per year), we expect that if women have two days with unprotected
acts on average during each cycle (e.g., 90% condom use, 20 acts per
cycle, and no other contraceptive method use), the 12-month
cumulative pregnancy probability would be 51%. Therefore, the
pregnancy probability of 43% at 12 months observed during this
study is not inconsistent with what the participant’s reported–89%
condom use and a coital frequency of 30 acts per month. Unless
adequate and well-controlled safety studies of microbicides in
pregnant women are conducted prior to the start of future HIV
preventionstudiestherebyallowingwomenwhobecomepregnantto
remain on study product, investigators should consider mandating
that all female participants who have reproductive potential must be
using an effective non-barrier contraceptive such as depot
medroxyprogesterone acetate(DMPA),combinedoralcontraceptive
pills (COCs), an intrauterine device (IUD), or a contraceptive
implant at least at the time of enrollment.
We did not observe a significant difference in the overall rate of
adverse events between participants receiving SAVVY and those
receiving placebo. The frequency of adverse events in the
reproductive tract/breast disorders (specifically symptoms of
vaginal or vulvar irritation) appeared higher in the SAVVY
group, but further subgroup analyses revealed no evidence that the
effect of SAVVY use was more pronounced among women with
more frequent exposure to the product. Whether the observed
increased risk for these events among the SAVVY users in the
subset of women who had fewer than average sexual acts and/or
fewer gel uses is a chance finding, a result of confounding due to
subgrouping by a post-randomization factor, or evidence of an
actual negative association between treatment effect and frequency
of intercourse, is unclear.
One limit of our study is generalizability. Although we did not
specifically recruit sex workers, women in our study averaged a
coital frequency of 7 acts per week and 5–6 different partners in
the last month. Thus conclusions should be interpreted cautiously
with regard to other populations.
The availability of study product did not appear to result in
increased risk taking behaviors among participants. During
enrollment, participants reported a mean of 9 coital acts per week
with a mean of 6 sexual partners in the previous 30 days. During
follow-up, participants reported a mean of 7 coital acts per week,
with a mean of 5–6 sexual partners in the previous 30 days.
Reported condom use during follow-up increased from 40%
during the last coital act prior to screening to over 89% at the first
follow-up visit and remained relatively constant throughout the
entire follow period.
Conclusion
As a new HIV prevention approach, microbicides could be used
with other prevention strategies such as condoms to reduce the
number of people who become infected with HIV. In our study,
SAVVY was not associated with increased adverse events overall
relative to placebo, but was associated with higher reporting of
reproductive adverse events. Our data are insufficient to conclude
whether SAVVY is effective at preventing HIV infection relative
to placebo. Phase III trials with larger numbers of seroconver-
sions are needed to determine the effectiveness, safety, and
feasibility of using microbicides for prevention of HIV infection in
women.
SUPPORTING INFORMATION
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0001312.s001 (0.05 MB
DOC)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0001312.s002 (0.74 MB
DOC)
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